Experimental Test Can Better Predict Breast Cancer Recurrence

BCS_Blog_DTOP_BelowTitle_336x280

Researchers have developed a new blood test that can more accurately predict breast cancer recurrence.

Researchers are constantly looking for ways to improve the treatment of and response to breast cancer, and the brilliant minds at Johns Hopkins Kimmel Cancer Center have designed a new experimental blood test that could prove to be an important diagnostic tool in the future.

It's called the cMethDNA assay, and according to researchers it can detect the presence of metastatic breast cancer DNA with up to 95 percent accuracy. Previously, the risk of recurrence for breast cancer survivors would only be measured if the patient complained of particular symptoms (like shortness of breath and bone aches). However, the new test allows medical professionals to monitor 10 specific genes, leading to more accurate diagnoses of breast cancer recurrence.

"The goal is to develop a test that could be administered routinely to alert the physician and patient as soon as possible of a return of the original cancer in a distant spot," Saraswati Sukumar, co-director of the Breast Cancer Program at the Johns Hopkins Kimmel Cancer Center, said in a statement. "With the development of cMethDNA, we've taken a first big step toward achieving this goal."

There is currently a patent pending on the test, and researchers plan to conduct several additional studies to confirm their exciting findings.

Lockerdome BCS – desktop
Medianet BCS
The Breast Cancer Site is a place where supporters and survivors come together to help fight breast cancer. In addition to sharing personal stories of hope, shopping for the cause, and signing petitions, visitors can take just a moment each day to click on a pink button to provide free mammograms for women in need. Visit The Breast Cancer Site and click today - it's free!